Aclarion Inc. (Nasdaq: ACON, ACONW), a Broomfield health care technology company specializing in identification of chronic low back pain locations, announced it has secured payer coverage for its Nociscan solution from Vitality, a leading UK private medical insurer. This expands Nociscan’s coverage to three of the four largest private health insurers in the UK.
With the inclusion of Vitality, nearly 60% of all private health insurance patients in greater London now have access to Nociscan. The service is already covered by AXA and Aviva, two other top private insurers.
The London Clinic, a major independent hospital in the UK, played a significant role in securing this coverage. Brent Ness, CEO of Aclarion, said, “With three of the top four private payer systems in greater London covering Nociscan, we expect to see further coverage and strong product adoption in the UK market.”
John Lorbiecki, CFO of Aclarion, added, “These significant payer coverage decisions represent a sea change in our business. As soon as insurance companies recognize new innovations with an assigned payment, the economics change considerably.”
Vitality holds an estimated 13% share of the UK private medical insurance market and insures about 1 million customers. The adoption of Nociscan by significant payers supports the move toward standardizing it as part of chronic low back pain treatments.
Low back pain is estimated to affect up to one third of the UK adult population each year. The London Spine Clinic, a specialist spinal unit, has integrated Nociscan as a decision support tool for diagnosing and treating chronic low back pain.
Nociscan is an evidence-supported SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine using chemical biomarkers. This data is processed through proprietary algorithms to help identify potential pain sources, providing critical insights when used alongside other diagnostic tools.